Skip to main content

Elotuzumab, Lenalidomide, and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma

Conference Correspondent - Conference Correspondent, ASH 2016 - Multiple Myeloma

Patients with high-risk smoldering multiple myeloma (SMM) have a 50% risk of progression to overt disease within 2 years. These patients have relatively strong immune systems compared with patients with more advanced myeloma; hence, the rationale to study immunotherapy in this population.

This phase 2 study aimed to determine the clinical benefit of early therapeutic intervention with the combination of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk SMM.

Patient eligibility was determined based on recently defined criteria for high-risk SMM.1 All enrolled patients received weekly elotuzumab (10 mg/kg) on days 1, 8, 15, and 22 for the first two 28-day cycles; lenalidomide on days 1 to 21; and dexamethasone 40 mg on days 1, 8, and 15. Patients were then allowed to continue on maintenance therapy with elotuzumab and lenalidomide.

A total of 51 patients were enrolled in this study. The median age of patients was 63 years, and the median number of cycles completed was 8 (range, 1-23). Of 47 evaluable patients, the overall response rate was 82.6%, including 2 complete responses, 6 very good partial responses, and 11 partial responses. The clinical benefit rate was 100%. Data showed that high-dose dexamethasone does not have a detrimental effect on the immune system in patients with SMM. Thus far, no patients have progressed to active multiple myeloma at 24 months of study.

Most commonly occurring treatment-related grade 3 toxicities included hypophosphatemia, neutropenia, decreased lymphocyte count, hypertension, pulmonary infection, and hypokalemia.

Researchers concluded that the combination of elotuzumab, lenalidomide, and dexamethasone is very well tolerated among patients with high-risk SMM. The high response rates seen in this otherwise untreated population suggest that early therapeutic intervention is worthy of consideration in patients with high-risk SMM.

Ghobrial IM, et al. ASH 2016. Abstract 976.

  1. Rajkumar, et al. Blood. 2014.
Related Items
Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Improved Quality of Life in Adults with Acute Bacterial Skin and Skin Structure Infections with Omadacycline or Linezolid Therapy
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Omadacycline In Vitro Activity Against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Integrated Safety Summary of Omadacycline, A Novel Aminomethylcycline Antibiotic
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Improvements in Remission and Low Disease Activity Achieved with Ongoing Sarilumab Treatment in Patients with RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Last modified: August 30, 2021